Effect of IFN-γ on Innate Immune Cells

Status Completed

Clinical Trial Summary

The investigators hypothesize that neutrophils and monocytes developed under the influence of Interferon- gamma-1b (IFN-γ-1b, Actimmune*) in vivo will display enhanced function across a broad range of activities related in large part to the transcriptional activation effects of this cytokine. The investigators will evaluate the effects of IFN-γ in healthy human subjects in vivo on gene expression, biologic activity markers, and functional activity of myeloid cells in single dose studies and in steady state studies.

Clinical Trial Description

Named for their potent ability to interfere and protect against viral infections, interferons (IFNs) have many regulatory effects on the immune system.1 Of the members of the two classes of these compounds, IFN-γ has the most diverse and powerful immune effects. Studies have mostly evaluated IFN-γ interactions with cells of adaptive immunity, including macrophages and lymphocytes. Effects on innate immunity, particularly polymorphonuclear leukocytes or neutrophils and monocytes are less well studied. However, investigations have suggested that IFN-γ may be involved in signal transduction, gene expression, the respiratory burst and neutrophil NADPH oxidase (Nox2) activity, phagocytosis, motility, microbicidal activity, and apoptosis. Not all of these functions are enhanced by IFN-γ; but the clinical use of this cytokine has been driven, in part by these results. For example, the primary motivation for initiating investigation of its beneficial clinical effects in Chronic Granulomatous Disease (CGD) was its effects on Nox2 activity.2 Most data in this area was based on studies using differentiated neutrophils from peripheral blood.1 However, the phenotype of neutrophils developed under the influence of this cytokine, not just changes expressed by exposure of differentiated cells to IFN-γ, is critical to understanding the physiologic effects of IFN-γ and the broad applications for its use in treatment of a range of human diseases. To expand their understanding of the role of IFN-γ in the development and functional integrity of the neutrophil, the investigators have completed a series of studies with PLB-985 cells in an in vitro culture system of myeloid cells. In this proposal, the investigators will evaluate innate immune activation and phagocyte function in healthy adult volunteers who are receiving IFN-γ. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02609932
Study type	Interventional
Source	University of Colorado, Denver
Contact
Status	Completed
Phase	Phase 1
Start date	July 2016
Completion date	February 2019

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT03278912` - Natural History of Intestinal Inflammation in People With Primary Immune Dysregulations
Recruiting	`NCT01652092` - Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies	N/A
Completed	`NCT04136028` - IL-1 Receptor Inhibitor for Granulomatous Complications in Patients With Chronic Granulomatous Disease	Early Phase 1
Recruiting	`NCT05687474` - Baby Detect : Genomic Newborn Screening
Terminated	`NCT03080480` - Pioglitazone Therapy for Chronic Granulomatous Disease	Phase 1/Phase 2
Terminated	`NCT00394316` - Gene Therapy for Chronic Granulomatous Disease	Early Phase 1
Recruiting	`NCT03910452` - Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide	Early Phase 1
Terminated	`NCT02282904` - Haploidentical Transplant for People With Chronic Granulomatous Disease Using Post Transplant Cyclophosphamide	Phase 1/Phase 2
Terminated	`NCT02926963` - Generation of Powerful Biological Tools for Understanding the Pathophysiology of Chronic Granulomatous Disease.	N/A
Completed	`NCT00006417` - Modified Stem Cell Transplantation Procedure for Treating Chronic Granulomatous Disease	Phase 2
Completed	`NCT00368446` - Genetic Disorders of Mucociliary Clearance in Nontuberculous Mycobacterial Lung Disease
Enrolling by invitation	`NCT03655223` - Early Check: Expanded Screening in Newborns
Recruiting	`NCT06162936` - Neutrophil Oxidative Burst in Early and Late Onset Pediatric Inflammatory Bowel Disease
Terminated	`NCT05915897` - Whole Blood Biospecimen Collection for Subjects With Chronic Granulomatous Disease (CGD)
Terminated	`NCT00325078` - Infliximab to Treat Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease	Phase 1/Phase 2
Completed	`NCT00001317` - A Phase IV Study of Recombinant Human Gamma Interferon in Patients With Chronic Granulomatous Diseases of Childhood	Phase 4
Enrolling by invitation	`NCT06253507` - pCCLCHIM-p47 (Lentiviral Vector Transduced CD34 Plus Cells) in Patients With p47 Autosomal Recessive Chronic Granulomatous Disease (AR-CGD)	Phase 1/Phase 2
Completed	`NCT03548818` - Role of Interferon-gamma 1-b (IFN-γ) on Cells of the Innate Immune System: Functional, Biochemical and Gene Expression Studies in Patients With Chronic Granulomatous Disease
Recruiting	`NCT01821781` - Immune Disorder HSCT Protocol	Phase 2
Completed	`NCT00578643` - Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous Disease	Phase 2